<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05796193</url>
  </required_header>
  <id_info>
    <org_study_id>28390</org_study_id>
    <nct_id>NCT05796193</nct_id>
  </id_info>
  <brief_title>Net Transition Initiative: Efficacy of Two Next-generation Nets for Control of Malaria in Cote d'Ivoire</brief_title>
  <official_title>Net Transition Initiative: Efficacy of Two Next-generation Nets for Control of Malaria in Cote d'Ivoire</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Pierre Richet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Ottawa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nevada, Las Vegas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator plan to conduct a three-arm cluster-randomized control trial which compares&#xD;
      two next generation of long-lasting Insecticidal Nets (LLINs); Veeralin®LLIN (PBO-py LLIN),&#xD;
      Interceptor G2 (chlorfenapyr-py LLIN) to a standard py-LLIN in the department of Tiebissou&#xD;
      Southern Bouake city, central Côte d'Ivoire.&#xD;
&#xD;
      The primary objective of the project is to evaluate the efficacy of chlorfenapyr-pyrethroid&#xD;
      and piperonyl-butoxide (PBO) synergist-pyrethroid LLINs on malaria case incidence in children&#xD;
      aged 6 months to 10 years compared to standard pyrethroid-only LLINs. The secondary&#xD;
      objectives are to evaluate the efficacy of the two intervention LLINs compared to the&#xD;
      standard LLIN on a) malaria infection prevalence in the general population (both children and&#xD;
      adults), b) vector density and c) entomological inoculation rate (EIR) (as a proxy for&#xD;
      malaria transmission). In addition, changes in phenotypic resistance intensity and selection&#xD;
      for molecular resistance mechanisms at baseline and 12 months post-LLIN distribution, in&#xD;
      sentinel villages in each treatment arm will be investigate.&#xD;
&#xD;
      It is vital to demonstrate that these next generation LLINs which are becoming the standard&#xD;
      of care in Sub Saharan AFRICA, are superior to standard py-LLIN in the most extreme&#xD;
      resistance areas as this is likely where alternative interventions will be most needed to&#xD;
      keep malaria control on track. The trial will generate the first epidemiological evidence on&#xD;
      the efficacy of PBO nets compared to py-LLIN in West Africa.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: The massive scale-up of long-lasting insecticidal nets (LLIN) has led to a major&#xD;
      reduction in malaria burden in many sub-Saharan African (SSA) countries. This progress is&#xD;
      threatened by the wide scale selection of insecticide resistant malaria vectors.&#xD;
&#xD;
      Study site: The study will be conducted in the department of Tiebissou (Gbeke Region in Lac&#xD;
      district) Southern Bouake city, central Côte d'Ivoire. The Lac district is characterized by&#xD;
      intense indoor malaria transmission with a prevalence of malaria reaching 51.3% in 2021 in&#xD;
      children of under 5 years of age and extremely high pyrethroid resistance intensity in the&#xD;
      main malaria vectors Anopheles gambiae s.s. and An. coluzzii.&#xD;
&#xD;
      Study design: Three-arm superiority, single blinded, cluster-randomised trial with village as&#xD;
      the unit of randomisation. The arms consist of; 1/ Veeralin LLIN, a net combining the&#xD;
      synergist PBO and the pyrethroid alpha-cypermethrin, 2/Interceptor G2, a mixture LLIN&#xD;
      incorporating two adulticides with different modes of action; chlorfenapyr and a pyrethroid&#xD;
      (alpha-cypermethrin), and 3/ the control arm: MAGNet LLIN, an alpha-cypermethrin-only LLIN.&#xD;
&#xD;
      Activities/Sample size:&#xD;
&#xD;
      A total of 33 villages (1 village = 1 cluster) with an average of 200 households will be&#xD;
      identified and mapped. Nets will be distributed at a central point following national&#xD;
      guidelines with 1 net for every 2 people.&#xD;
&#xD;
      To compare incidence of malaria cases between each intervention study arm and the control&#xD;
      arm, a cohort of 50 children (45 + 5 to account for loss to follow up) will be recruited per&#xD;
      cluster in 33 clusters for 12 months follow up to be able to detect a 35% relative reduction&#xD;
      in malaria cases per child per year (rate ratio 0.65) between the intervention and the&#xD;
      reference arms, assuming transmission in the control arm is 1.2 malaria cases per year with a&#xD;
      coefficient of variation of 0.29 between clusters. The children will be visited twice a month&#xD;
      during the transmission season (April to November) and once a month during the dry season.&#xD;
&#xD;
      Malaria infection prevalence cross-sectional surveys will be conducted, at baseline, 6 and 12&#xD;
      months after LLIN distribution. 50 people of all ages will be randomly selected from each of&#xD;
      the 33 clusters (11 clusters per arm x 3 arms) and tested for malaria using RDT. The study&#xD;
      will have 80% power to detect a relative 35% lower prevalence (prevalence ratio 0.65 in each&#xD;
      intervention arm (VEERALLIN or Interceptor G2) relative to standard LLIN, assuming a&#xD;
      prevalence of 50% in the control arm and a coefficient of variation of 0.3.&#xD;
&#xD;
      Vector density over 12 months will be followed using Human Landing Collection (HLC) indoor&#xD;
      and outdoor with collection in 6 households in every cluster every 2 months. Assuming a mean&#xD;
      mosquito density of 28 in the control arm, and a 60% reduction in mosquitoes in the&#xD;
      intervention arms, with a coefficient of variation of 0.55 between clusters, this will give&#xD;
      80% power to detect differences at each timepoint.&#xD;
&#xD;
      Insecticide resistance intensity will be monitored at baseline and post intervention using&#xD;
      adapted CDC bottle assays. The mechanism involved in resistance to pyrethroid and&#xD;
      chlorfenapyr will be screened.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2023</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>malaria case incidence by malaria rapid diagnostic test HRP2/pLDH [pf/pan]</measure>
    <time_frame>Over one year follow up</time_frame>
    <description>Incidence of malaria cases (fever above 37.5C or history of a fever in the last 48 hours and a positive RDT) in children aged 6 months to 10 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Malaria infection prevalence by malaria rapid diagnostic test HRP2/pLDH [pf/pan]</measure>
    <time_frame>Baseline</time_frame>
    <description>Malaria infection prevalence (by RDT) in the study population of all ages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malaria infection prevalence by malaria rapid diagnostic test HRP2/pLDH [pf/pan]</measure>
    <time_frame>6 months post intervention</time_frame>
    <description>Malaria infection prevalence (by RDT) in the study population of all ages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malaria infection prevalence by malaria rapid diagnostic test HRP2/pLDH [pf/pan]</measure>
    <time_frame>12 months post intervention</time_frame>
    <description>Malaria infection prevalence (by RDT) in the study population of all ages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vector Density per person per night using human indoor and outdoor landing catches</measure>
    <time_frame>Over one year follow up</time_frame>
    <description>Indoor and outdoor Anopheles density per night per person</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sporozoite rate in Anopheles detected using Enzyme Linked Immuno-Sorbent Assay (ELISA) circumsporozoite protein technique. landing catches</measure>
    <time_frame>Over one year follow up</time_frame>
    <description>Proportion of Anopheles with malaria circumsporozoites in salivary gland</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of Plasmodium spp infective malaria vectors collected per person per night</measure>
    <time_frame>Over one year follow up</time_frame>
    <description>Entomological inoculation rate measure as vector density x sporozoite rate</description>
  </secondary_outcome>
  <other_outcome>
    <measure>gSG6-P1 IgG seroprevalence using ELISA technique</measure>
    <time_frame>baseline</time_frame>
    <description>Serological responses to mosquito salivary peptides: Blood spots on filter paper will be utilized to measure the level of antibodies in residents blood as a proxy for exposure to mosquito bites</description>
  </other_outcome>
  <other_outcome>
    <measure>gSG6-P1 IgG seroprevalence using ELISA technique</measure>
    <time_frame>12 months post intervention</time_frame>
    <description>Serological responses to mosquito salivary peptides: Blood spots on filter paper will be utilized to measure the level of antibodies in residents blood as a proxy for exposure to mosquito bites</description>
  </other_outcome>
  <other_outcome>
    <measure>30 minutes mortality in wild Anopheles post exposure to various concentration insecticide in CDC bottle assay</measure>
    <time_frame>Baseline</time_frame>
    <description>Phenotypic resistance to alpha-cypermethrin, PBO + alpha-cypermethrin and chlorfenapyr using WHO cylinder and CDC bottle bioassays will be conducted</description>
  </other_outcome>
  <other_outcome>
    <measure>24 hours mortality in wild Anopheles post exposure to various concentration insecticide in CDC bottle assay</measure>
    <time_frame>Baseline</time_frame>
    <description>Phenotypic resistance to alpha-cypermethrin, PBO + alpha-cypermethrin and chlorfenapyr using WHO cylinder and CDC bottle bioassays will be conducted</description>
  </other_outcome>
  <other_outcome>
    <measure>72 hours mortality in wild Anopheles post exposure to various concentration insecticide in CDC bottle assay</measure>
    <time_frame>Baseline</time_frame>
    <description>Phenotypic resistance to alpha-cypermethrin, PBO + alpha-cypermethrin and chlorfenapyr using WHO cylinder and CDC bottle bioassays will be conducted</description>
  </other_outcome>
  <other_outcome>
    <measure>30 minutes mortality in wild Anopheles post exposure to various concentration insecticide in CDC bottle assay</measure>
    <time_frame>12 months post intervention</time_frame>
    <description>Phenotypic resistance to alpha-cypermethrin, PBO + alpha-cypermethrin and chlorfenapyr using WHO cylinder and CDC bottle bioassays will be conducted</description>
  </other_outcome>
  <other_outcome>
    <measure>24 hours mortality in wild Anopheles post exposure to various concentration insecticide in CDC bottle assay</measure>
    <time_frame>12 months post intervention</time_frame>
    <description>Phenotypic resistance to alpha-cypermethrin, PBO + alpha-cypermethrin and chlorfenapyr using WHO cylinder and CDC bottle bioassays will be conducted</description>
  </other_outcome>
  <other_outcome>
    <measure>72 hours mortality in wild Anopheles post exposure to various concentration insecticide in CDC bottle assay</measure>
    <time_frame>12 months post intervention</time_frame>
    <description>Phenotypic resistance to alpha-cypermethrin, PBO + alpha-cypermethrin and chlorfenapyr using WHO cylinder and CDC bottle bioassays will be conducted</description>
  </other_outcome>
  <other_outcome>
    <measure>Relative fold change in expression of metabolic genes</measure>
    <time_frame>Baseline</time_frame>
    <description>Selection for resistance will be monitored by measuring changes in levels of metabolic enzyme expression between wild population of Anopheles and susceptible reference Anopheles</description>
  </other_outcome>
  <other_outcome>
    <measure>Relative fold change in expression of metabolic genes</measure>
    <time_frame>12 months post intervention</time_frame>
    <description>Selection for resistance will be monitored by measuring changes in levels of metabolic enzyme expression between wild population of Anopheles and susceptible reference Anopheles</description>
  </other_outcome>
  <other_outcome>
    <measure>Concentration of PBO, alpha-cypermethrin and Chlorfenapyr in g per kg in mosquito net</measure>
    <time_frame>Before net distribution</time_frame>
    <description>Concentration of chemical will be assessed by HPLC</description>
  </other_outcome>
  <other_outcome>
    <measure>24 hours and 72 hours mortality in a susceptible colony of Anopheles gambiae after exposure to new pieces of mosquito nets</measure>
    <time_frame>Before net distribution</time_frame>
    <description>Bio-efficacy testing will be conducted in standard WHO cone bio-assay and/or tunnel test</description>
  </other_outcome>
  <other_outcome>
    <measure>24 hours and 72 hours mortality in a resistant colony of Anopheles gambiae after exposure to new pieces of mosquito nets</measure>
    <time_frame>Before net distribution</time_frame>
    <description>Bio-efficacy testing will be conducted in standard WHO cone bio-assay and/or tunnel test</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1650</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>Py-PBO LLIN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Veeralin is a long-lasting net of 130 deniers containing the pyrethroid insecticide alpha-cypermethrin 6.0 g/kg (216 mg/m2) and the synergist piperonyl butoxide (PBO) 2.2 g/kg (79.2 mg/m2) and manufactured by VKA polymers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Py-CFP LLIN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interceptor® G2 is a long-lasting dual insecticide treated nets of 100 deniers combining Alpha-cypermethrin 2.4 g/kg (100 mg/m2) and Chlorfenapyr 4.8 g/kg (200 mg/m2) manufactured by BASF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Py LLIN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MAGNet® is a long-lasting net of 150 deniers containing the pyrethroid insecticide alpha-cypermethrin 5.8 g/kg (261 mg/m2) only and manufactured by VKA polymers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Alpha-cypermethrin and PBO LLIN</intervention_name>
    <description>Veeralin Long lasting insecticidal net with Alpha-cypermethrin Pyrethroid insecticide and PBO</description>
    <arm_group_label>Py-PBO LLIN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Alpha-cypermethrin and Clorfenapyr LLIN</intervention_name>
    <description>Interceptor G2 dual active ingredient LLIN with with Alpha-cypermethrin Pyrethroid insecticide and Clorfenapyr</description>
    <arm_group_label>Py-CFP LLIN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Alpha-cypermethrin only LLIN</intervention_name>
    <description>reference: standard pyrethroid LLIN</description>
    <arm_group_label>Py LLIN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For adults: willing to participate and provide consent&#xD;
&#xD;
          -  For children: Having a parents/adult caregiver willing to provide written consent for&#xD;
             the household and clinical survey and assent for children over 10&#xD;
&#xD;
          -  Residing in the village over the last 3 months&#xD;
&#xD;
          -  Be aged 6 months to 9 years old at time of recruitment (for the cohort)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children who are expected to be non-resident over the period of study will be excluded&#xD;
             (for the cohort)&#xD;
&#xD;
          -  Dwelling not found or vacant during the survey (for prevalence and entomological&#xD;
             surveys)&#xD;
&#xD;
          -  No adult caregiver capable to give informed consent (All activities)&#xD;
&#xD;
          -  Habitants/selected participants severely ill&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Raphael NGUESSAN, PhD</last_name>
    <phone>+225 0779404001</phone>
    <email>raphael.n'guessan@lshtm.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aphonsine KOFFI, PhD</last_name>
    <phone>+225 0707620886</phone>
    <email>koffi_alphonsine@yahoo.fr</email>
  </overall_contact_backup>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>February 27, 2023</study_first_submitted>
  <study_first_submitted_qc>March 21, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 21, 2023</last_update_submitted>
  <last_update_submitted_qc>March 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anopheles density</keyword>
  <keyword>Entomological inoculation rate</keyword>
  <keyword>Malaria case incidence</keyword>
  <keyword>Malaria infection prevalence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

